Inhibitory mechanism of serpins - Mobility of the c-terminal region of the reactive-site loop

被引:25
作者
Hopkins, PCR [1 ]
Chang, WSW [1 ]
Wardell, MR [1 ]
Stone, SR [1 ]
机构
[1] UNIV CAMBRIDGE,DEPT HAEMATOL,MRC CTR,CAMBRIDGE CB2 2QH,ENGLAND
基金
英国惠康基金;
关键词
D O I
10.1074/jbc.272.7.3905
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The reactive-site loops of serpins are characterized by a defined mobility where the loop adopts a new secondary structure as an essential part of the inhibitory process. While the importance of mobility in the N-terminal region of the reactive-site loop has been well studied, the role of mobility in the C-terminal portion has not been investigated. The requirements for mobility of the C-terminal portion of the reactive-site loop of alpha(1)-antitrypsin were investigated by creating a disulfide bridge between the P'(3) residue and residue 283 near the top of strand 2C; this disulfide would restrict the mobility of the C-terminal portion of the reactive-site loop by locking together strands 1 and 2 of the C beta-sheet. The engineered disulfide bond had no effect on the inhibitory activity of alpha(1)-antitrypsin, indicating that there is no requirement for mobility in this region of the molecule. Moreover, these results, coupled with those from molecular modeling, indicate that insertion into the A beta-sheet of the intact reactive-loop beyond P-12 is not rate-limiting for the formation of the stable complex. The engineered disulfide bond should also prove useful in the creation of more stable serpin variants; for example, such a bond in plasminogen activator inhibitor-1 would prevent it from becoming latent by locking strand 1C onto the C beta-sheet.
引用
收藏
页码:3905 / 3909
页数:5
相关论文
共 30 条
[1]   CRYSTAL-STRUCTURE OF CLEAVED HUMAN ALPHA-1-ANTICHYMOTRYPSIN AT 2.7-A RESOLUTION AND ITS COMPARISON WITH OTHER SERPINS [J].
BAUMANN, U ;
HUBER, R ;
BODE, W ;
GROSSE, D ;
LESJAK, M ;
LAURELL, CB .
JOURNAL OF MOLECULAR BIOLOGY, 1991, 218 (03) :595-606
[2]  
BJORK I, 1992, J BIOL CHEM, V267, P19047
[3]   NATURAL PROTEIN PROTEINASE-INHIBITORS AND THEIR INTERACTION WITH PROTEINASES [J].
BODE, W ;
HUBER, R .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1992, 204 (02) :433-451
[4]   Ligand binding: proteinase protein inhibitor interactions [J].
Bode, Wolfram ;
Huber, Robert .
CURRENT OPINION IN STRUCTURAL BIOLOGY, 1991, 1 (01) :45-52
[5]   THROMBOEMBOLIC DISEASE DUE TO THERMOLABILE CONFORMATIONAL-CHANGES OF ANTITHROMBIN ROUEN-VI (187-ASN-]ASP) [J].
BRUCE, D ;
PERRY, DJ ;
BORG, JY ;
CARRELL, RW ;
WARDELL, MR .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 94 (06) :2265-2274
[6]   BIOLOGICAL IMPLICATIONS OF A 3-ANGSTROM STRUCTURE OF DIMERIC ANTITHROMBIN [J].
CARRELL, RW ;
STEIN, PE ;
WARDELL, MR ;
FERMI, G .
STRUCTURE, 1994, 2 (04) :257-270
[7]   COOH-TERMINAL SUBSTITUTIONS IN THE SERPIN C1 INHIBITOR THAT CAUSE LOOP OVERINSERTION AND SUBSEQUENT MULTIMERIZATION [J].
ELDERING, E ;
VERPY, E ;
ROEM, D ;
MEO, T ;
TOSI, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (06) :2579-2587
[8]   MODELING THE INTACT FORM OF THE ALPHA-1-PROTEINASE INHIBITOR [J].
ENGH, RA ;
WRIGHT, HT ;
HUBER, R .
PROTEIN ENGINEERING, 1990, 3 (06) :469-477
[9]   RELEASE OF A 2-CHAIN FORM OF ANTI-THROMBIN FROM THE ANTITHROMBIN-THROMBIN COMPLEX [J].
FISH, WW ;
BJORK, I .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1979, 101 (01) :31-38
[10]  
Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8